NEW YORK (GenomeWeb) – Cancer Genetics said today that New York State has approved the company's Focus::Myeloid next-generation sequencing-based panel for myeloid malignancies.

The 54-gene panel provides information that clinicians can use to diagnose, provide prognosis, determine treatment options, and provide risk stratification for patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.